| Literature DB >> 19823069 |
Isabelle Thuret1, Marie-Laure Chaix, Catherine Tamalet, Véronique Reliquet, Ghislaine Firtion, Joëlle Tricoire, Christian Rabaud, Pierre Frange, Hugues Aumaître, Stéphane Blanche.
Abstract
Twelve heavily pretreated, perinatally infected adolescents in virological failure were treated with a combination of raltegravir, r-darunavir and etravirine, as part of an expanded access program in France. After a 12-month median follow-up, viral load was <400 copies/ml in 11 (<50 in six). No grade > 2 side effects were recorded. Additional data and marketing authorizations are awaited, but preliminary results in adolescents with extensive multidrug resistant virus are encouraging.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19823069 DOI： 10.1097/QAD.0b013e328331a456
Source DB: PubMed Journal: AIDS ISSN： 0269-9370 Impact factor: 4.177